• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Haoxi Health Technology Limited

    3/6/26 4:15:33 PM ET
    $HAO
    Advertising
    Consumer Discretionary
    Get the next $HAO alert in real time by email
    6-K 1 ea0280399-6k_haoxi.htm REPORT OF FOREIGN PRIVATE ISSUER
     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of March 2026

     

    Commission File Number: 001-41933

     

    Haoxi Health Technology Limited

    (Translation of registrant’s name into English)

     

    Room 801, Tower C, Floor 8, Building 103

    Huizhongli, Chaoyang District

    Beijing, China

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒           Form 40-F ☐

     

     

     

     

     

     

    Change of Directors

     

    On March 6, 2026, Mr. Jianbing Zhang, a director of Haoxi Health Technology Limited’s (the “Company”), resigned from his position due to personal reasons, effective immediately.

     

    The resignation of Mr. Jianbing Zhang was not the result of any disagreements with the Company on any matter related to the operations, policies, or practices of the Company.

     

    The board of directors (“Board”) of the Company appointed Mr. Chuanjie Hu as a director of Board, effective on March 6, 2026. The Board determined that Mr. Chuanjie Hu satisfies the “independence” requirements under the corporate governance rules of The Nasdaq Stock Market LLC and Rule 10A-3 under the Securities Exchange Act of 1934, as amended. Mr. Hu will serve as the chairman of the nominating and corporate governance committee, a member of the compensation committee, and a member of the audit committee. The biographical information of Mr. Chuanjie Hu is set forth below.

     

    Mr. Chuanjie Hu, aged 40, has extensive experience in business management and corporate operations. Since November 2018, Mr. Hu has served as the General Manager of Beijing Chuanna Impression Culture Co., Ltd., a China-based company engaged in cultural and business development activities, where he is responsible for overseeing the company’s business development strategies and overall operational management. From September 2009 to August 2018, Mr. Hu served as Business Group Manager at Tingyi (Cayman Islands) Holding Corp., a multinational food and beverage company, where he was responsible for business development initiatives and strategic planning of the company’s business operations. Mr. Hu received a bachelor’s degree in International Economics and Trade from Huaiyin Institute of Technology in 2009.

     

    Mr. Chuanjie Hu does not have a family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item404(a) of Regulation S-K.

     

    The Company entered into an offer letter (the “Offer Letter”) with Mr. Chuanjie Hu. He will not receive compensation for his services as a director of the Board. The Offer Letter is filed hereto as Exhibit 10.1.

     

    1

     

     

    EXHIBIT INDEX

     

    Number   Description of Exhibit
         
    10.1   The Offer Letter, dated March 6, 2026 by and between the Company and Chuanjie Hu

     

    2

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Haoxi Health Technology Limited
         
      By: /s/ Zhen Fan
        Zhen Fan
        Chief Executive Officer
         
    Date: March 6, 2026    

     

    3

     

    Get the next $HAO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HAO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HAO
    SEC Filings

    View All

    SEC Form 6-K filed by Haoxi Health Technology Limited

    6-K - Haoxi Health Technology Ltd (0001954594) (Filer)

    3/6/26 4:15:33 PM ET
    $HAO
    Advertising
    Consumer Discretionary

    SEC Form 6-K filed by Haoxi Health Technology Limited

    6-K - Haoxi Health Technology Ltd (0001954594) (Filer)

    2/10/26 4:15:01 PM ET
    $HAO
    Advertising
    Consumer Discretionary

    SEC Form 6-K filed by Haoxi Health Technology Limited

    6-K - Haoxi Health Technology Ltd (0001954594) (Filer)

    1/23/26 5:19:27 PM ET
    $HAO
    Advertising
    Consumer Discretionary

    $HAO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HAOXI HEALTH TECHNOLOGY and Eaglepoint AI Forge Strategic Partnership to Enter AI-Powered Health Management Track

    BEIJING, March 03, 2026 (GLOBE NEWSWIRE) -- HAOXI HEALTH TECHNOLOGY LIMITED (NASDAQ:HAO) (the "Haoxi Health"), a U.S. publicly listed company, and Eaglepoint AI Inc., a subsidiary of Global Mofy AI Limited (NASDAQ:GMM), today jointly announced the signing of a three-year strategic cooperation agreement. The two parties will jointly commit R&D, data, and channel resources to launch an AI health management platform in China. Haoxi Health believes that this partnership marks its's exploration of potential opportunities in the AI-enabled healthcare sector. This collaboration also represents the first time that Eaglepoint AI has deployed its Aquila data engine and multimodal model evaluation sy

    3/3/26 7:30:00 AM ET
    $GMM
    $HAO
    Computer Software: Programming Data Processing
    Technology
    Advertising
    Consumer Discretionary

    Haoxi Health Technology Limited Launches Customized Livestreaming Agency Strategy

    BEIJING, April 21, 2025 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the "Company" or "HAO"), an online marketing solution provider headquartered in Beijing, China, announced that Beijing Haoxi Digital Technology Co., Ltd. ("Haoxi Beijing"), a wholly-owned subsidiary of the Company, has launched its customized livestreaming agency strategy and is progressing partnership discussions on personalized livestreaming agency services with several long-term clients of medical aesthetics, marking a new strategic step in the Company's business development roadmap. Driven by the growing demand for personalized and high-quality services in the healthcare and medical aesthetics sectors, and

    4/21/25 9:45:17 AM ET
    $HAO
    Advertising
    Consumer Discretionary

    Haoxi Health Technology Limited Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

    BEIJING, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the "Company" or "HAO"), an online marketing solution provider headquartered in Beijing, China, today announced that it received a formal notification from the Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company's Class A ordinary shares, par value US$0.0025 each (the "Ordinary Shares") to maintain a minimum bid price of $1.00 per share. The Nasdaq staff made this determination of compliance after the closing bid price of the Company's Ordinary Shares has been at $1.00 per share or greater for the last 10 consecutive business d

    2/11/25 8:30:00 AM ET
    $HAO
    Advertising
    Consumer Discretionary

    $HAO
    Leadership Updates

    Live Leadership Updates

    View All

    Haoxi Health Technology Limited Facilitates International Humanitarian Aid Efforts Amid Global Challenges

    Haoxi Health Technology Limited (the "Company" or "HAO"), an online marketing solution provider headquartered in Beijing, China, today announced that against the backdrop of increasing global challenges, the Company is mobilizing its resources to actively fulfill its corporate social responsibility and is closely monitoring international humanitarian needs and collaborating with relevant organizations and groups to provide essential support for international medical aid. Amidst evolving global dynamics, numerous regions face pressing humanitarian needs. The Company, renowned for its expertise in digital marketing and commitment to social responsibility, is leveraging its capabilities to a

    6/9/24 8:00:00 PM ET
    $HAO
    Advertising
    Consumer Discretionary